Diabetic Retinopathy Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

Diabetic Retinopathy Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “Diabetic Retinopathy Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Diabetic Retinopathy Pipeline Report

  • DelveInsight’s Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment.
  • The leading companies working in the Diabetic Retinopathy Market include Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
  • Promising Diabetic Retinopathy Pipeline Therapies in the various stages of development include Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.
  • November 2023: Alkahest Inc. announced a study of Phase 2 clinical trials for AKST4290. A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants with Moderately Severe to Severe Diabetic Retinopathy (CAPRI). This study is designed to evaluate the efficacy of AKST4290 administered at a total daily dose (TDD) of 800 mg daily (400 mg twice daily [b.i.d.]) compared with placebo over a 24-week dosing period in participants with moderately severe non-proliferative diabetic retinopathy (NPDR) to severe NPDR.
  • November 2023: Kodiak Sciences Inc. announced a study of Phase 3 clinical trials for KSI-301. This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
  • October 2023: Bayer announced a study of Phase 2 clinical trials for Runcaciguat (BAY1101042). This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography for central assessment of the diabetic retinopathy severity score, or DRSS. Two-step DRSS improvement at 24 weeks of treatment will be the primary efficacy endpoint. DRSS assessments are repeated after completion of 48 weeks of treatment. In addition, vision threatening complications will be recorded throughout the study and assessed as secondary efficacy endpoint.
  • October 2023: RemeGen Co. Ltd announced a study of Phase 2 clinical trials for RC28-E injection. This is a randomized, open-label, multicenter study of the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) in the treatment of patients with moderately severe to severe nonproliferative diabetic retinopathy.

 

Request a sample and discover the recent advances in Diabetic Retinopathy Treatment Drugs @ Diabetic Retinopathy Pipeline Report

 

In the Diabetic Retinopathy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Retinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Diabetic Retinopathy Overview

Diabetic retinopathy (DR) is a major complication of diabetes mellitus (DM), which remains a leading cause of visual loss in working-age populations. The retina contains photoreceptor cells that function in the process of visual transduction, i.e., transforming light signals to nerve impulses eventually transmitted from the optic nerve to the brain forming an image.

 

Find out more about Diabetic Retinopathy Therapeutics Assessment @ Diabetic Retinopathy Preclinical and Discovery Stage Products

 

Diabetic Retinopathy Emerging Drugs Profile

  • KSI-301: Kodiak Sciences
  • Brolucizumab: Novartis
  • RGX 314: Regenxbio Inc.
  • OTT-166: OcuTerra Therapeutics
  • OTX-TKI: Ocular Therapeutix

 

Diabetic Retinopathy Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the Diabetic Retinopathy therapies. The Diabetic Retinopathy companies which have their Diabetic Retinopathy drug candidates in the most advanced stage, i.e. phase III include, Kodiak Sciences.

 

DelveInsight’s Diabetic Retinopathy pipeline report covers around 55+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging Diabetic Retinopathy Pipeline Therapies @ Diabetic Retinopathy Clinical Trials Assessment

 

Scope of the Diabetic Retinopathy Pipeline Report

  • Coverage- Global
  • Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
  • Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.

 

Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Diabetic Retinopathy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Diabetic Retinopathy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. KSI-301: Kodiak Sciences
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. RGX 314: Regenxbio Inc
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. OTX-TKI: Ocular Therapeutix
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Diabetic Retinopathy Key Companies
  21. Diabetic Retinopathy Key Products
  22. Diabetic Retinopathy- Unmet Needs
  23. Diabetic Retinopathy- Market Drivers and Barriers
  24. Diabetic Retinopathy- Future Perspectives and Conclusion
  25. Diabetic Retinopathy Analyst Views
  26. Diabetic Retinopathy Key Companies
  27. Appendix

 

For further information on the Diabetic Retinopathy Pipeline therapeutics, reach out to Diabetic Retinopathy Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market